Has Globus Medical (GMED) Fallen Far Enough To Be A Bargain?

Globus Medical stock has pulled back in recent weeks, yet over three years it has still delivered a strong gain. The current valuation checks now lean on the cheap side for a medical technology business of its size.

• Shares are up 51.8% over the past three years. This puts recent weakness into context as a pause after a solid multi year climb.
• The CE mark for the Excelsius3D imaging system in the EU and UK can support growth expectations. At the same time, execution risk around commercial rollout and adoption may weigh on how much investors are willing to pay for that growth.
• The broader valuation work-up suggests Globus Medical screens as relatively inexpensive overall, with a value score of 6 pointing to more of a bargain than a stretch on standard checks.

The issue now is whether the recent share price pullback has already priced in the key risks, or if Globus Medical still embeds expectations that are too rich for the fundamentals on offer.

Spot fresh opportunities alongside Globus Medical by scanning our handpicked group of resilient healthcare and medtech names in the solid balance sheet and fundamentals stocks screener (24 results).

Does Globus Medical Look Undervalued on Earnings?

The P/E ratio is often a useful measure for Globus Medical because investors frequently look at earnings-based metrics first for profitable healthcare companies. On this basis, the stock trades on about 18.7x earnings, which is well below the Medical Equipment industry average of roughly 25.8x and the peer group near 38.1x.

A tailored fair P/E multiple for Globus Medical is around 29.7x, reflecting how the market might usually price the business given its size, margins and risk profile. That figure is materially higher than the current 18.7x, which points to a sizeable discount. Despite the recent Excelsius3D CE mark potentially supporting sentiment, the earnings multiple still leaves the stock priced below what these checks suggest as a more typical level.

On this P/E yardstick, Globus Medical stock appears undervalued compared with both its sector and its own fair multiple estimate.

See what the numbers say about this price — find out in our valuation breakdown.

The Globus Medical Narrative: What Would Justify Today's Price?

Globus Medical's valuation puzzle only really comes into focus when you spell out what would need to happen to its growth, margins and earnings for the share price to look either too low or too demanding. That is what Simply Wall St Narratives on the Community page are built to do, and each one frames its implied fair value as a thesis about the business that you can watch play out over time rather than a static number on a screen.

One of the top community narratives on Globus Medical: 11% undervalued

"There are substantial integration and execution risks following the recent NuVasive and Nevro acquisitions, including potential disruption to the sales force, operational inefficiencies, and uncertainty about realizing synergies..."

Read one of the top narratives on Globus Medical

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

The Bottom Line

Globus Medical screens as undervalued on earnings, with the current P/E sitting well below both sector levels and its own tailored multiple. That discount only becomes appealing if the group can handle integration work around recent acquisitions while keeping margins and earnings quality intact. The key debate is whether the lower valuation reflects temporary caution or a lasting reset in what investors are prepared to pay for this business. For now, everything hinges on how convincingly management executes on commercial rollouts and integration, and whether the market eventually awards Globus Medical a valuation closer to peer levels again.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com